本文へ移動
cccskills
無料GitHub で公開

enda-annual-evaluation-over-under-replacement

This skill guides annual evaluation of patients with primary adrenal insufficiency (PAI) for symptoms and signs of glucocorticoid and mineralocorticoid over- or under-replacement. Use during annual follow-up when assessing for weight changes, blood pressure abnormalities, edema, or symptoms such as fatigue, insomnia, or salt craving.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.1 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Evaluate PAI Patients Annually for Symptoms and Signs of Over- and Under-Replacement

STEP 1 — Gather Information

Collect weight, supine and standing blood pressure, presence of peripheral edema, and symptoms: glucocorticoid excess (weight gain, insomnia, hyperglycemia, peripheral edema), glucocorticoid deficiency (fatigue, weight loss, nausea, hyperpigmentation), mineralocorticoid excess (hypertension, hypokalemia), mineralocorticoid deficiency (salt craving, postural hypotension, hyperkalemia, hyponatremia). Review current glucocorticoid and mineralocorticoid doses.

STEP 2 — Rule In / Rule Out

Determine if any symptoms or signs suggestive of over- or under-replacement are present. If none are identified, consider replacement adequate and proceed to routine annual care; if any are present, proceed to classification.

STEP 3 — Classify or Stratify

Classify findings into: glucocorticoid over-replacement (e.g., weight gain, insomnia, edema), glucocorticoid under-replacement (fatigue, weight loss, hypotension, hyperpigmentation), mineralocorticoid over-replacement (hypertension, hypokalemia), mineralocorticoid under-replacement (salt craving, postural hypotension, hyperkalemia, hyponatremia), or mixed patterns based on clinical assessment.

STEP 4 — Decide

For glucocorticoid over-replacement, consider reducing the glucocorticoid dose; for under-replacement, consider increasing the glucocorticoid dose. For mineralocorticoid over-replacement, consider reducing fludrocortisone; for under-replacement, consider increasing fludrocortisone or advising adequate salt intake. If replacement appears adequate, maintain current regimen and reassess at next annual visit.

Clinical Guardrails / Mimics / Pitfalls

Do not attribute symptoms solely to PAI without excluding concurrent illness, other endocrine disorders, or medication side effects. Avoid dose adjustments based on isolated abnormal labs without clinical correlation. Do not rely on ACTH levels to guide dosing in adequately replaced patients. Refrain from making dose changes during acute illness without addressing stress‑dosing needs first.

Concrete Clinical Example

A 48‑year‑old man with PAI on hydrocortisone 25 mg daily and fludrocortisone 100 µg daily reports 4 kg weight gain, difficulty sleeping, and mild leg edema over the past year; blood pressure is 142/88 mmHg, no salt craving or postural dizziness. Assessment indicates glucocorticoid over‑replacement; hydrocortisone is reduced to 20 mg daily with re‑evaluation in 3 months.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する